Selective androgen receptor degrader (SARD) to overcome antiandrogen resistance in castration-resistant prostate cancer
- Chinese Academy of Medical Sciences & Peking Union Medical College, China
- Zhejiang Normal University, China
- Beijing Hospital, China
Abstract
In patients with castration-resistant prostate cancer (CRPC), clinical resistances such as androgen receptor (AR) mutation, AR overexpression, and AR splice variants (ARVs) limit the effectiveness of second-generation antiandrogens (SGAs). Several strategies have been implemented to develop novel antiandrogens to circumvent the occurring resistance. Here, we found and identified a bifunctional small molecule Z15, which is both an effective AR antagonist and a selective AR degrader. Z15 could directly interact with the ligand-binding domain (LBD) and activation function-1 region of AR, and promote AR degradation through the proteasome pathway. In vitro and in vivo studies showed that Z15 efficiently suppressed AR, AR mutants and ARVs transcription activity, downregulated mRNA and protein levels of AR downstream target genes, thereby overcoming AR LBD mutations, AR amplification, and ARVs-induced SGAs resistance in CRPC. In conclusion, our data illustrate the synergistic importance of AR antagonism and degradation in advanced prostate cancer treatment.
Data availability
Data Availability: All data generated or analysed during this study are included in the manuscript and supporting source files. The RNA sequence data could be found in the following link: https://bigd.big.ac.cn/gsa-human/browse/HRA000921. The mass spectrometry proteomics data have been deposited to the ProteomeXchange Consortium via the PRIDE partner repository with the dataset identifier PXD035721. PRIDE - Proteomics Identification Database (ebi.ac.uk).
Article and author information
Author details
Funding
National Natural Science Foundation of China (22077115,81672559,81311120299)
- Jinming Zhou
National Natural Science Foundation of China (82104231)
- Meng Wu
China Postdoctoral Science Foundation (2021M700504)
- Meng Wu
The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.
Ethics
Animal experimentation: All animal experiments have been approved by the Ethics Committee of Nanjing Lambda Pharmaceutical Co.,Ltd (Reference number: IACUC-20210902).
Copyright
© 2023, Wu et al.
This article is distributed under the terms of the Creative Commons Attribution License permitting unrestricted use and redistribution provided that the original author and source are credited.
Metrics
-
- 3,921
- views
-
- 573
- downloads
-
- 12
- citations
Views, downloads and citations are aggregated across all versions of this paper published by eLife.
Download links
A two-part list of links to download the article, or parts of the article, in various formats.
Downloads (link to download the article as PDF)
Open citations (links to open the citations from this article in various online reference manager services)
Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)
Selective androgen receptor degrader (SARD) to overcome antiandrogen resistance in castration-resistant prostate cancer
eLife 12:e70700.
https://doi.org/10.7554/eLife.70700
